Literature DB >> 11957146

CTNNB1 mutations and beta-catenin expression in endometrial carcinomas.

Pilar Machin1, Lluis Catasus, Cristina Pons, Josefina Muñoz, Xavier Matias-Guiu, Jaime Prat.   

Abstract

Mutations in the beta-catenin gene (CTNNB 1) with abnormal nuclear accumulation of beta-catenin have recently been identified in endometrial carcinoma (EC). Their relationship with microsatellite instability (MI) is unclear. It has been suggested that matrix metalloproteinase-7 (MMP-7) and cyclin D1 (cD) genes are targets for beta-catenin activation. DNA from 73 patients with EC was obtained from tumor and normal tissue (59 endometrioid and 14 nonendometrioid). CTNNB 1 mutations in exon 3 were assessed by single-strand conformation polymorphism and DNA sequencing. The results were correlated with immunostaining for beta-catenin, MMP-7, and cD. Three (CA)n repeats and mononucleotide tracts BAT 25 and BAT 26 had been previously used for MI analysis. CTNNB1 mutations were identified in 15 ECs (20.5%), all of them endometrioid carcinomas (15 of 59; 25.4%). They occurred in 6 of 19 MI-positive ECs (31.5%) and in 9 of 54 MI-negative ECs (16.6%). Eleven of the 15 CTNNB 1-mutated ECs showed beta-catenin nuclear immunostaining (P <.05). MMP-7 expression (>50% cells) was observed in 23 ECs, with 7 of these showing CTNNB 1 mutations. Significant expression of cD (>50% cells) was detected in 8 ECs, with 5 of these exhibiting CTNNB 1 mutations (P <.05). The results confirm that beta-catenin plays a role in endometrial carcinogenesis, particularly in endometrioid carcinomas. The results also suggest that MMP-7 and particularly cD may be targets of beta-catenin activation in ECs. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11957146     DOI: 10.1053/hupa.2002.30723

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  30 in total

1.  Differential vimentin expression in ovarian and uterine corpus endometrioid adenocarcinomas: diagnostic utility in distinguishing double primaries from metastatic tumors.

Authors:  Mohamed M Desouki; Sarah J Kallas; Dineo Khabele; Marta A Crispens; Omar Hameed; Oluwole Fadare
Journal:  Int J Gynecol Pathol       Date:  2014-05       Impact factor: 2.762

2.  A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear beta-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression.

Authors:  Giuseppe Pelosi; Aldo Scarpa; Giulia Veronesi; Lorenzo Spaggiari; Barbara Del Curto; Patrick S Moore; Patrick Maisonneuve; Angelica Sonzogni; Michele Masullo; Giuseppe Viale
Journal:  Virchows Arch       Date:  2005-09-13       Impact factor: 4.064

3.  Negative feedback loop in T cell activation through IkappaB kinase-induced phosphorylation and degradation of Bcl10.

Authors:  Camille Lobry; Tatiana Lopez; Alain Israël; Robert Weil
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-09       Impact factor: 11.205

4.  CK2beta is expressed in endometrial carcinoma and has a role in apoptosis resistance and cell proliferation.

Authors:  Judit Pallares; David Llobet; Maria Santacana; Nuria Eritja; Ana Velasco; Dolors Cuevas; Susana Lopez; Victor Palomar-Asenjo; Andree Yeramian; Xavier Dolcet; Xavier Matias-Guiu
Journal:  Am J Pathol       Date:  2008-12-04       Impact factor: 4.307

5.  Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer.

Authors:  Thanh H Dellinger; Kestutis Planutis; Danielle D Jandial; Ramez N Eskander; Micaela E Martinez; Xiaolin Zi; Bradley J Monk; Randall F Holcombe
Journal:  Gynecol Oncol       Date:  2012-04-30       Impact factor: 5.482

Review 6.  The emerging genomic landscape of endometrial cancer.

Authors:  Matthieu Le Gallo; Daphne W Bell
Journal:  Clin Chem       Date:  2013-10-29       Impact factor: 8.327

7.  Intranodal palisaded myofibroblastoma: another mesenchymal neoplasm with CTNNB1 (β-catenin gene) mutations: clinicopathologic, immunohistochemical, and molecular genetic study of 18 cases.

Authors:  William B Laskin; Jerzy P Lasota; John F Fetsch; Anna Felisiak-Golabek; Zeng-Feng Wang; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2015-02       Impact factor: 6.394

8.  The coexistence of ERBB2, INT2, and CMYC oncogene amplifications and PTEN gene mutations in endometrial carcinoma.

Authors:  Bozena Konopka; Aneta Janiec-Jankowska; Zygmunt Paszko; Marian Goluda
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-09       Impact factor: 4.553

9.  DcR1 expression in endometrial carcinomas.

Authors:  Jordi Tarragona; Nuria Llecha; Maria Santacana; Susana Lopez; Sonia Gatius; David Llobet; Xavier Dolcet; Victor Palomar-Asenjo; Francisco Javier Gonzalez-Tallada; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2009-11-20       Impact factor: 4.064

10.  The genomics and genetics of endometrial cancer.

Authors:  Andrea J O'Hara; Daphne W Bell
Journal:  Adv Genomics Genet       Date:  2012-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.